source
- Moonwalk Biosciences raises $70M to move RNAi obesity drug MW101 toward first-in-human trials in 2027Moonwalk Biosciences, an obesity drug developer backed by Eli Lilly, announced a $70 million Series B financing. The funding will support its lead RNAi candidate, MW101, which in mouse studies pro…
- Novartis' pelacarsen fails Phase 3, casting doubt on Lp(a) lowering strategyNovartis announced that its antisense drug pelacarsen failed to meet the primary endpoint in the Phase 3 Lp(a)HORIZON trial. The study was intended to determine whether the drug’s ability to lower…